Summary of decision: niraparib funded for ovarian cancer
This news item is more than two years old
The information on this page may no longer be accurate. If you have any questions, you can email us at media@pharmac.govt.nz
Pharmac is funding niraparib for ovarian cancer through an agreement with GlaxoSmithKline New Zealand (GSK) as part of a bundle deal.